#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0009] These goals may be achieved by using a combination of different compounds or vectors.
1-1	0-1	[	_	_	
1-2	1-5	0009	_	_	
1-3	5-6	]	_	_	
1-4	7-12	These	_	_	
1-5	13-18	goals	_	_	
1-6	19-22	may	_	_	
1-7	23-25	be	_	_	
1-8	26-34	achieved	_	_	
1-9	35-37	by	_	_	
1-10	38-43	using	_	_	
1-11	44-45	a	_	_	
1-12	46-57	combination	_	_	
1-13	58-60	of	_	_	
1-14	61-70	different	_	_	
1-15	71-80	compounds	_	_	
1-16	81-83	or	_	_	
1-17	84-91	vectors	_	_	
1-18	91-92	.	_	_	

#Text=Notably, there are some compounds or vectors, which overcome at least some of these barriers.
#Text=[0010] Most usually, transfection, e.g. of nucleic acids, is carried out using viral or non-viral vectors.
2-1	93-100	Notably	_	_	
2-2	100-101	,	_	_	
2-3	102-107	there	_	_	
2-4	108-111	are	_	_	
2-5	112-116	some	_	_	
2-6	117-126	compounds	_	_	
2-7	127-129	or	_	_	
2-8	130-137	vectors	_	_	
2-9	137-138	,	_	_	
2-10	139-144	which	_	_	
2-11	145-153	overcome	_	_	
2-12	154-156	at	_	_	
2-13	157-162	least	_	_	
2-14	163-167	some	_	_	
2-15	168-170	of	_	_	
2-16	171-176	these	_	_	
2-17	177-185	barriers	_	_	
2-18	185-186	.	_	_	
2-19	187-188	[	_	_	
2-20	188-192	0010	_	_	
2-21	192-193	]	_	_	
2-22	194-198	Most	_	_	
2-23	199-206	usually	_	_	
2-24	206-207	,	_	_	
2-25	208-220	transfection	_	_	
2-26	220-221	,	_	_	
2-27	222-225	e.g	_	_	
2-28	225-226	.	_	_	
2-29	227-229	of	_	_	
2-30	230-237	nucleic	_	_	
2-31	238-243	acids	_	_	
2-32	243-244	,	_	_	
2-33	245-247	is	_	_	
2-34	248-255	carried	_	_	
2-35	256-259	out	_	_	
2-36	260-265	using	_	_	
2-37	266-271	viral	_	_	
2-38	272-274	or	_	_	
2-39	275-284	non-viral	_	_	
2-40	285-292	vectors	_	_	
2-41	292-293	.	_	_	

#Text=For successful delivery, these viral or non-viral vectors must be able to overcome the above mentioned barriers.
3-1	294-297	For	_	_	
3-2	298-308	successful	_	_	
3-3	309-317	delivery	_	_	
3-4	317-318	,	_	_	
3-5	319-324	these	_	_	
3-6	325-330	viral	_	_	
3-7	331-333	or	_	_	
3-8	334-343	non-viral	_	_	
3-9	344-351	vectors	_	_	
3-10	352-356	must	_	_	
3-11	357-359	be	_	_	
3-12	360-364	able	_	_	
3-13	365-367	to	_	_	
3-14	368-376	overcome	_	_	
3-15	377-380	the	_	_	
3-16	381-386	above	_	_	
3-17	387-396	mentioned	_	_	
3-18	397-405	barriers	_	_	
3-19	405-406	.	_	_	

#Text=The most successful gene therapy strategies available today rely on the use of viral vectors, such as adenoviruses, adeno-associated viruses, retroviruses, and herpes viruses.
4-1	407-410	The	_	_	
4-2	411-415	most	_	_	
4-3	416-426	successful	_	_	
4-4	427-431	gene	_	_	
4-5	432-439	therapy	_	_	
4-6	440-450	strategies	_	_	
4-7	451-460	available	_	_	
4-8	461-466	today	_	_	
4-9	467-471	rely	_	_	
4-10	472-474	on	_	_	
4-11	475-478	the	_	_	
4-12	479-482	use	_	_	
4-13	483-485	of	_	_	
4-14	486-491	viral	_	_	
4-15	492-499	vectors	_	_	
4-16	499-500	,	_	_	
4-17	501-505	such	_	_	
4-18	506-508	as	_	_	
4-19	509-521	adenoviruses	_	_	
4-20	521-522	,	_	_	
4-21	523-539	adeno-associated	_	_	
4-22	540-547	viruses	_	_	
4-23	547-548	,	_	_	
4-24	549-561	retroviruses	_	_	
4-25	561-562	,	_	_	
4-26	563-566	and	_	_	
4-27	567-573	herpes	_	_	
4-28	574-581	viruses	_	_	
4-29	581-582	.	_	_	

#Text=Viral vectors are able to mediate gene transfer with high efficiency and the possibility of long-term gene expression, and satisfy 2 out of 3 criteria.
5-1	583-588	Viral	_	_	
5-2	589-596	vectors	_	_	
5-3	597-600	are	_	_	
5-4	601-605	able	_	_	
5-5	606-608	to	_	_	
5-6	609-616	mediate	_	_	
5-7	617-621	gene	_	_	
5-8	622-630	transfer	_	_	
5-9	631-635	with	_	_	
5-10	636-640	high	_	_	
5-11	641-651	efficiency	_	_	
5-12	652-655	and	_	_	
5-13	656-659	the	_	_	
5-14	660-671	possibility	_	_	
5-15	672-674	of	_	_	
5-16	675-684	long-term	_	_	
5-17	685-689	gene	_	_	
5-18	690-700	expression	_	_	
5-19	700-701	,	_	_	
5-20	702-705	and	_	_	
5-21	706-713	satisfy	_	_	
5-22	714-715	2	_	_	
5-23	716-719	out	_	_	
5-24	720-722	of	_	_	
5-25	723-724	3	_	_	
5-26	725-733	criteria	_	_	
5-27	733-734	.	_	_	

#Text=However, the acute immune response, immunogenicity, and insertion mutagenesis uncovered in gene therapy clinical trials have raised serious safety concerns about some commonly used viral vectors.
#Text=[0011] A solution to this problem may be found in the use of non-viral vectors.
6-1	735-742	However	*[1]	6-37[2_1]	
6-2	742-743	,	*[1]	_	
6-3	744-747	the	*[1]	_	
6-4	748-753	acute	*[1]	_	
6-5	754-760	immune	*[1]	_	
6-6	761-769	response	*[1]	_	
6-7	769-770	,	*[1]	_	
6-8	771-785	immunogenicity	*[1]	_	
6-9	785-786	,	*[1]	_	
6-10	787-790	and	*[1]	_	
6-11	791-800	insertion	*[1]	_	
6-12	801-812	mutagenesis	*[1]	_	
6-13	813-822	uncovered	*[1]	_	
6-14	823-825	in	*[1]	_	
6-15	826-830	gene	*[1]	_	
6-16	831-838	therapy	*[1]	_	
6-17	839-847	clinical	*[1]	_	
6-18	848-854	trials	*[1]	_	
6-19	855-859	have	*[1]	_	
6-20	860-866	raised	*[1]	_	
6-21	867-874	serious	*[1]	_	
6-22	875-881	safety	*[1]	_	
6-23	882-890	concerns	*[1]	_	
6-24	891-896	about	*[1]	_	
6-25	897-901	some	*[1]	_	
6-26	902-910	commonly	*[1]	_	
6-27	911-915	used	*[1]	_	
6-28	916-921	viral	*[1]	_	
6-29	922-929	vectors	*[1]	_	
6-30	929-930	.	*[1]	_	
6-31	931-932	[	_	_	
6-32	932-936	0011	_	_	
6-33	936-937	]	_	_	
6-34	938-939	A	_	_	
6-35	940-948	solution	_	_	
6-36	949-951	to	_	_	
6-37	952-956	this	*[2]	_	
6-38	957-964	problem	*[2]	_	
6-39	965-968	may	_	_	
6-40	969-971	be	_	_	
6-41	972-977	found	_	_	
6-42	978-980	in	_	_	
6-43	981-984	the	_	_	
6-44	985-988	use	_	_	
6-45	989-991	of	_	_	
6-46	992-1001	non-viral	_	_	
6-47	1002-1009	vectors	_	_	
6-48	1009-1010	.	_	_	

#Text=Although non-viral vectors are not as efficient as viral vectors, many non-viral vectors have been developed to provide a safer alternative in gene therapy.
7-1	1011-1019	Although	_	_	
7-2	1020-1029	non-viral	_	_	
7-3	1030-1037	vectors	_	_	
7-4	1038-1041	are	_	_	
7-5	1042-1045	not	_	_	
7-6	1046-1048	as	_	_	
7-7	1049-1058	efficient	_	_	
7-8	1059-1061	as	_	_	
7-9	1062-1067	viral	_	_	
7-10	1068-1075	vectors	_	_	
7-11	1075-1076	,	_	_	
7-12	1077-1081	many	_	_	
7-13	1082-1091	non-viral	_	_	
7-14	1092-1099	vectors	_	_	
7-15	1100-1104	have	_	_	
7-16	1105-1109	been	_	_	
7-17	1110-1119	developed	_	_	
7-18	1120-1122	to	_	_	
7-19	1123-1130	provide	_	_	
7-20	1131-1132	a	_	_	
7-21	1133-1138	safer	_	_	
7-22	1139-1150	alternative	_	_	
7-23	1151-1153	in	_	_	
7-24	1154-1158	gene	_	_	
7-25	1159-1166	therapy	_	_	
7-26	1166-1167	.	_	_	

#Text=Methods of nonviral gene delivery have been explored using physical (carrier-free gene delivery) and chemical approaches (synthetic vector-based gene delivery).
8-1	1168-1175	Methods	_	_	
8-2	1176-1178	of	_	_	
8-3	1179-1187	nonviral	_	_	
8-4	1188-1192	gene	_	_	
8-5	1193-1201	delivery	_	_	
8-6	1202-1206	have	_	_	
8-7	1207-1211	been	_	_	
8-8	1212-1220	explored	_	_	
8-9	1221-1226	using	_	_	
8-10	1227-1235	physical	_	_	
8-11	1236-1237	(	_	_	
8-12	1237-1249	carrier-free	_	_	
8-13	1250-1254	gene	_	_	
8-14	1255-1263	delivery	_	_	
8-15	1263-1264	)	_	_	
8-16	1265-1268	and	_	_	
8-17	1269-1277	chemical	_	_	
8-18	1278-1288	approaches	_	_	
8-19	1289-1290	(	_	_	
8-20	1290-1299	synthetic	_	_	
8-21	1300-1312	vector-based	_	_	
8-22	1313-1317	gene	_	_	
8-23	1318-1326	delivery	_	_	
8-24	1326-1327	)	_	_	
8-25	1327-1328	.	_	_	

#Text=Physical approaches usually include needle injection, electroporation, gene gun, ultrasound, and hydrodynamic delivery, employ a physical force that permeates the cell membrane and facilitates intracellular gene transfer.
9-1	1329-1337	Physical	_	_	
9-2	1338-1348	approaches	_	_	
9-3	1349-1356	usually	_	_	
9-4	1357-1364	include	_	_	
9-5	1365-1371	needle	_	_	
9-6	1372-1381	injection	_	_	
9-7	1381-1382	,	_	_	
9-8	1383-1398	electroporation	_	_	
9-9	1398-1399	,	_	_	
9-10	1400-1404	gene	_	_	
9-11	1405-1408	gun	_	_	
9-12	1408-1409	,	_	_	
9-13	1410-1420	ultrasound	_	_	
9-14	1420-1421	,	_	_	
9-15	1422-1425	and	_	_	
9-16	1426-1438	hydrodynamic	_	_	
9-17	1439-1447	delivery	_	_	
9-18	1447-1448	,	_	_	
9-19	1449-1455	employ	_	_	
9-20	1456-1457	a	_	_	
9-21	1458-1466	physical	_	_	
9-22	1467-1472	force	_	_	
9-23	1473-1477	that	_	_	
9-24	1478-1487	permeates	_	_	
9-25	1488-1491	the	_	_	
9-26	1492-1496	cell	_	_	
9-27	1497-1505	membrane	_	_	
9-28	1506-1509	and	_	_	
9-29	1510-1521	facilitates	_	_	
9-30	1522-1535	intracellular	_	_	
9-31	1536-1540	gene	_	_	
9-32	1541-1549	transfer	_	_	
9-33	1549-1550	.	_	_	

#Text=The chemical approaches typically use synthetic or naturally occurring compounds (cationic lipids, cationic polymers, lipid-polymer hybrid systems) as carriers to deliver the transgene into cells.
10-1	1551-1554	The	_	_	
10-2	1555-1563	chemical	_	_	
10-3	1564-1574	approaches	_	_	
10-4	1575-1584	typically	_	_	
10-5	1585-1588	use	_	_	
10-6	1589-1598	synthetic	_	_	
10-7	1599-1601	or	_	_	
10-8	1602-1611	naturally	_	_	
10-9	1612-1621	occurring	_	_	
10-10	1622-1631	compounds	_	_	
10-11	1632-1633	(	_	_	
10-12	1633-1641	cationic	_	_	
10-13	1642-1648	lipids	_	_	
10-14	1648-1649	,	_	_	
10-15	1650-1658	cationic	_	_	
10-16	1659-1667	polymers	_	_	
10-17	1667-1668	,	_	_	
10-18	1669-1682	lipid-polymer	_	_	
10-19	1683-1689	hybrid	_	_	
10-20	1690-1697	systems	_	_	
10-21	1697-1698	)	_	_	
10-22	1699-1701	as	_	_	
10-23	1702-1710	carriers	_	_	
10-24	1711-1713	to	_	_	
10-25	1714-1721	deliver	_	_	
10-26	1722-1725	the	_	_	
10-27	1726-1735	transgene	_	_	
10-28	1736-1740	into	_	_	
10-29	1741-1746	cells	_	_	
10-30	1746-1747	.	_	_	

#Text=Although significant progress has been made in the basic science and applications of various nonviral gene delivery systems, the majority of nonviral approaches is still much less efficient than viral vectors, especially for in vivo gene delivery (see e.g.
11-1	1748-1756	Although	_	_	
11-2	1757-1768	significant	_	_	
11-3	1769-1777	progress	_	_	
11-4	1778-1781	has	_	_	
11-5	1782-1786	been	_	_	
11-6	1787-1791	made	_	_	
11-7	1792-1794	in	_	_	
11-8	1795-1798	the	_	_	
11-9	1799-1804	basic	_	_	
11-10	1805-1812	science	_	_	
11-11	1813-1816	and	_	_	
11-12	1817-1829	applications	_	_	
11-13	1830-1832	of	_	_	
11-14	1833-1840	various	_	_	
11-15	1841-1849	nonviral	_	_	
11-16	1850-1854	gene	_	_	
11-17	1855-1863	delivery	_	_	
11-18	1864-1871	systems	_	_	
11-19	1871-1872	,	_	_	
11-20	1873-1876	the	_	_	
11-21	1877-1885	majority	_	_	
11-22	1886-1888	of	_	_	
11-23	1889-1897	nonviral	_	_	
11-24	1898-1908	approaches	_	_	
11-25	1909-1911	is	_	_	
11-26	1912-1917	still	_	_	
11-27	1918-1922	much	_	_	
11-28	1923-1927	less	_	_	
11-29	1928-1937	efficient	_	_	
11-30	1938-1942	than	_	_	
11-31	1943-1948	viral	_	_	
11-32	1949-1956	vectors	_	_	
11-33	1956-1957	,	_	_	
11-34	1958-1968	especially	_	_	
11-35	1969-1972	for	_	_	
11-36	1973-1975	in	_	_	
11-37	1976-1980	vivo	_	_	
11-38	1981-1985	gene	_	_	
11-39	1986-1994	delivery	_	_	
11-40	1995-1996	(	_	_	
11-41	1996-1999	see	_	_	
11-42	2000-2003	e.g	_	_	
11-43	2003-2004	.	_	_	

#Text=Gao et al.
12-1	2005-2008	Gao	_	_	
12-2	2009-2011	et	_	_	
12-3	2012-2014	al	_	_	
12-4	2014-2015	.	_	_	

#Text=The AAPS Journal 2007; 9(1) Article 9).
#Text=[0012] Over the past decade, attractive prospects for a substantial improvement in the cellular delivery of nucleic acids have been announced that were supposed to result from their physical assembly or chemical ligation to so-called cell penetrating peptides (CPPs) also denoted as protein-transduction domains (PTDs) (see Foerg and Merkle, (2008, supra)), CPPs represent short peptide sequences of 10 to about 30 amino acids which can cross the plasma membrane of mammalian cells and may thus offer unprecedented opportunities for cellular drug delivery.
13-1	2016-2019	The	_	_	
13-2	2020-2024	AAPS	_	_	
13-3	2025-2032	Journal	_	_	
13-4	2033-2037	2007	_	_	
13-5	2037-2038	;	_	_	
13-6	2039-2040	9	_	_	
13-7	2040-2041	(	_	_	
13-8	2041-2042	1	_	_	
13-9	2042-2043	)	_	_	
13-10	2044-2051	Article	_	_	
13-11	2052-2053	9	_	_	
13-12	2053-2054	)	_	_	
13-13	2054-2055	.	_	_	
13-14	2056-2057	[	_	_	
13-15	2057-2061	0012	_	_	
13-16	2061-2062	]	_	_	
13-17	2063-2067	Over	_	_	
13-18	2068-2071	the	_	_	
13-19	2072-2076	past	_	_	
13-20	2077-2083	decade	_	_	
13-21	2083-2084	,	_	_	
13-22	2085-2095	attractive	_	_	
13-23	2096-2105	prospects	_	_	
13-24	2106-2109	for	_	_	
13-25	2110-2111	a	_	_	
13-26	2112-2123	substantial	_	_	
13-27	2124-2135	improvement	_	_	
13-28	2136-2138	in	_	_	
13-29	2139-2142	the	_	_	
13-30	2143-2151	cellular	_	_	
13-31	2152-2160	delivery	_	_	
13-32	2161-2163	of	_	_	
13-33	2164-2171	nucleic	_	_	
13-34	2172-2177	acids	_	_	
13-35	2178-2182	have	_	_	
13-36	2183-2187	been	_	_	
13-37	2188-2197	announced	_	_	
13-38	2198-2202	that	_	_	
13-39	2203-2207	were	_	_	
13-40	2208-2216	supposed	_	_	
13-41	2217-2219	to	_	_	
13-42	2220-2226	result	_	_	
13-43	2227-2231	from	_	_	
13-44	2232-2237	their	_	_	
13-45	2238-2246	physical	_	_	
13-46	2247-2255	assembly	_	_	
13-47	2256-2258	or	_	_	
13-48	2259-2267	chemical	_	_	
13-49	2268-2276	ligation	_	_	
13-50	2277-2279	to	_	_	
13-51	2280-2289	so-called	_	_	
13-52	2290-2294	cell	_	_	
13-53	2295-2306	penetrating	_	_	
13-54	2307-2315	peptides	_	_	
13-55	2316-2317	(	_	_	
13-56	2317-2321	CPPs	_	_	
13-57	2321-2322	)	_	_	
13-58	2323-2327	also	_	_	
13-59	2328-2335	denoted	_	_	
13-60	2336-2338	as	_	_	
13-61	2339-2359	protein-transduction	_	_	
13-62	2360-2367	domains	_	_	
13-63	2368-2369	(	_	_	
13-64	2369-2373	PTDs	_	_	
13-65	2373-2374	)	_	_	
13-66	2375-2376	(	_	_	
13-67	2376-2379	see	_	_	
13-68	2380-2385	Foerg	_	_	
13-69	2386-2389	and	_	_	
13-70	2390-2396	Merkle	_	_	
13-71	2396-2397	,	_	_	
13-72	2398-2399	(	_	_	
13-73	2399-2403	2008	_	_	
13-74	2403-2404	,	_	_	
13-75	2405-2410	supra	_	_	
13-76	2410-2411	)	_	_	
13-77	2411-2412	)	_	_	
13-78	2412-2413	,	_	_	
13-79	2414-2418	CPPs	_	_	
13-80	2419-2428	represent	_	_	
13-81	2429-2434	short	_	_	
13-82	2435-2442	peptide	_	_	
13-83	2443-2452	sequences	_	_	
13-84	2453-2455	of	_	_	
13-85	2456-2458	10	_	_	
13-86	2459-2461	to	_	_	
13-87	2462-2467	about	_	_	
13-88	2468-2470	30	_	_	
13-89	2471-2476	amino	_	_	
13-90	2477-2482	acids	_	_	
13-91	2483-2488	which	_	_	
13-92	2489-2492	can	_	_	
13-93	2493-2498	cross	_	_	
13-94	2499-2502	the	_	_	
13-95	2503-2509	plasma	_	_	
13-96	2510-2518	membrane	_	_	
13-97	2519-2521	of	_	_	
13-98	2522-2531	mammalian	_	_	
13-99	2532-2537	cells	_	_	
13-100	2538-2541	and	_	_	
13-101	2542-2545	may	_	_	
13-102	2546-2550	thus	_	_	
13-103	2551-2556	offer	_	_	
13-104	2557-2570	unprecedented	_	_	
13-105	2571-2584	opportunities	_	_	
13-106	2585-2588	for	_	_	
13-107	2589-2597	cellular	_	_	
13-108	2598-2602	drug	_	_	
13-109	2603-2611	delivery	_	_	
13-110	2611-2612	.	_	_	

#Text=Nearly all of these peptides comprise a series of cationic amino acids in combination with a sequence, which forms an .alpha.
14-1	2613-2619	Nearly	_	_	
14-2	2620-2623	all	_	_	
14-3	2624-2626	of	_	_	
14-4	2627-2632	these	_	_	
14-5	2633-2641	peptides	_	_	
14-6	2642-2650	comprise	_	_	
14-7	2651-2652	a	_	_	
14-8	2653-2659	series	_	_	
14-9	2660-2662	of	_	_	
14-10	2663-2671	cationic	_	_	
14-11	2672-2677	amino	_	_	
14-12	2678-2683	acids	_	_	
14-13	2684-2686	in	_	_	
14-14	2687-2698	combination	_	_	
14-15	2699-2703	with	_	_	
14-16	2704-2705	a	_	_	
14-17	2706-2714	sequence	_	_	
14-18	2714-2715	,	_	_	
14-19	2716-2721	which	_	_	
14-20	2722-2727	forms	_	_	
14-21	2728-2730	an	_	_	
14-22	2731-2732	.	_	_	
14-23	2732-2737	alpha	_	_	
14-24	2737-2738	.	_	_	

#Text=-helix at low pH.
15-1	2738-2739	-	_	_	
15-2	2739-2744	helix	_	_	
15-3	2745-2747	at	_	_	
15-4	2748-2751	low	_	_	
15-5	2752-2754	pH	_	_	
15-6	2754-2755	.	_	_	

#Text=As the pH is continuously lowered in vivo by proton pumps, a conformational change of the peptide is usually initiated rapidly.
16-1	2756-2758	As	_	_	
16-2	2759-2762	the	_	_	
16-3	2763-2765	pH	_	_	
16-4	2766-2768	is	_	_	
16-5	2769-2781	continuously	_	_	
16-6	2782-2789	lowered	_	_	
16-7	2790-2792	in	_	_	
16-8	2793-2797	vivo	_	_	
16-9	2798-2800	by	_	_	
16-10	2801-2807	proton	_	_	
16-11	2808-2813	pumps	_	_	
16-12	2813-2814	,	_	_	
16-13	2815-2816	a	_	_	
16-14	2817-2831	conformational	_	_	
16-15	2832-2838	change	_	_	
16-16	2839-2841	of	_	_	
16-17	2842-2845	the	_	_	
16-18	2846-2853	peptide	_	_	
16-19	2854-2856	is	_	_	
16-20	2857-2864	usually	_	_	
16-21	2865-2874	initiated	_	_	
16-22	2875-2882	rapidly	_	_	
16-23	2882-2883	.	_	_	

#Text=This helix motif mediates an insertion into the membrane of the endosome leading to a release of its content into the cytoplasma (see Foerg and Merkle, (2008, supra); and Vives, E., P.
17-1	2884-2888	This	_	_	
17-2	2889-2894	helix	_	_	
17-3	2895-2900	motif	_	_	
17-4	2901-2909	mediates	_	_	
17-5	2910-2912	an	_	_	
17-6	2913-2922	insertion	_	_	
17-7	2923-2927	into	_	_	
17-8	2928-2931	the	_	_	
17-9	2932-2940	membrane	_	_	
17-10	2941-2943	of	_	_	
17-11	2944-2947	the	_	_	
17-12	2948-2956	endosome	_	_	
17-13	2957-2964	leading	_	_	
17-14	2965-2967	to	_	_	
17-15	2968-2969	a	_	_	
17-16	2970-2977	release	_	_	
17-17	2978-2980	of	_	_	
17-18	2981-2984	its	_	_	
17-19	2985-2992	content	_	_	
17-20	2993-2997	into	_	_	
17-21	2998-3001	the	_	_	
17-22	3002-3012	cytoplasma	_	_	
17-23	3013-3014	(	_	_	
17-24	3014-3017	see	_	_	
17-25	3018-3023	Foerg	_	_	
17-26	3024-3027	and	_	_	
17-27	3028-3034	Merkle	_	_	
17-28	3034-3035	,	_	_	
17-29	3036-3037	(	_	_	
17-30	3037-3041	2008	_	_	
17-31	3041-3042	,	_	_	
17-32	3043-3048	supra	_	_	
17-33	3048-3049	)	_	_	
17-34	3049-3050	;	_	_	
17-35	3051-3054	and	_	_	
17-36	3055-3060	Vives	_	_	
17-37	3060-3061	,	_	_	
17-38	3062-3063	E	_	_	
17-39	3063-3064	.	_	_	
17-40	3064-3065	,	_	_	
17-41	3066-3067	P	_	_	
17-42	3067-3068	.	_	_	

#Text=Brodin, et al. (1997).
18-1	3069-3075	Brodin	_	_	
18-2	3075-3076	,	_	_	
18-3	3077-3079	et	_	_	
18-4	3080-3082	al	_	_	
18-5	3082-3083	.	_	_	
18-6	3084-3085	(	_	_	
18-7	3085-3089	1997	_	_	
18-8	3089-3090	)	_	_	
18-9	3090-3091	.	_	_	

#Text="A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus."
19-1	3092-3093	"	_	_	
19-2	3093-3094	A	_	_	
19-3	3095-3104	truncated	_	_	
19-4	3105-3108	HIV	_	_	
19-5	3108-3109	-	_	_	
19-6	3109-3110	1	_	_	
19-7	3111-3114	Tat	_	_	
19-8	3115-3122	protein	_	_	
19-9	3123-3128	basic	_	_	
19-10	3129-3135	domain	_	_	
19-11	3136-3143	rapidly	_	_	
19-12	3144-3156	translocates	_	_	
19-13	3157-3164	through	_	_	
19-14	3165-3168	the	_	_	
19-15	3169-3175	plasma	_	_	
19-16	3176-3184	membrane	_	_	
19-17	3185-3188	and	_	_	
19-18	3189-3200	accumulates	_	_	
19-19	3201-3203	in	_	_	
19-20	3204-3207	the	_	_	
19-21	3208-3212	cell	_	_	
19-22	3213-3220	nucleus	_	_	
19-23	3220-3221	.	_	_	
19-24	3221-3222	"	_	_	

#Text=J Biol Chem 272(25): 16010-7).
20-1	3223-3224	J	_	_	
20-2	3225-3229	Biol	_	_	
20-3	3230-3234	Chem	_	_	
20-4	3235-3238	272	_	_	
20-5	3238-3239	(	_	_	
20-6	3239-3241	25	_	_	
20-7	3241-3242	)	_	_	
20-8	3242-3243	:	_	_	
20-9	3244-3249	16010	_	_	
20-10	3249-3250	-	_	_	
20-11	3250-3251	7	_	_	
20-12	3251-3252	)	_	_	
20-13	3252-3253	.	_	_	

#Text=Despite these advantages, a major obstacle to CPP mediated drug delivery is thought to consist in the often rapid metabolic clearance of the peptides when in contact or passing the enzymatic barriers of epithelia and endothelia.
21-1	3254-3261	Despite	_	_	
21-2	3262-3267	these	_	_	
21-3	3268-3278	advantages	_	_	
21-4	3278-3279	,	_	_	
21-5	3280-3281	a	_	_	
21-6	3282-3287	major	_	_	
21-7	3288-3296	obstacle	_	_	
21-8	3297-3299	to	_	_	
21-9	3300-3303	CPP	_	_	
21-10	3304-3312	mediated	_	_	
21-11	3313-3317	drug	_	_	
21-12	3318-3326	delivery	_	_	
21-13	3327-3329	is	_	_	
21-14	3330-3337	thought	_	_	
21-15	3338-3340	to	_	_	
21-16	3341-3348	consist	_	_	
21-17	3349-3351	in	_	_	
21-18	3352-3355	the	_	_	
21-19	3356-3361	often	_	_	
21-20	3362-3367	rapid	_	_	
21-21	3368-3377	metabolic	_	_	
21-22	3378-3387	clearance	_	_	
21-23	3388-3390	of	_	_	
21-24	3391-3394	the	_	_	
21-25	3395-3403	peptides	_	_	
21-26	3404-3408	when	_	_	
21-27	3409-3411	in	_	_	
21-28	3412-3419	contact	_	_	
21-29	3420-3422	or	_	_	
21-30	3423-3430	passing	_	_	
21-31	3431-3434	the	_	_	
21-32	3435-3444	enzymatic	_	_	
21-33	3445-3453	barriers	_	_	
21-34	3454-3456	of	_	_	
21-35	3457-3466	epithelia	_	_	
21-36	3467-3470	and	_	_	
21-37	3471-3481	endothelia	_	_	
21-38	3481-3482	.	_	_	

#Text=In conclusion, metabolic stability of CPPs represents an important biopharmaceutical factor for their cellular bioavailability.
22-1	3483-3485	In	_	_	
22-2	3486-3496	conclusion	_	_	
22-3	3496-3497	,	_	_	
22-4	3498-3507	metabolic	_	_	
22-5	3508-3517	stability	_	_	
22-6	3518-3520	of	_	_	
22-7	3521-3525	CPPs	_	_	
22-8	3526-3536	represents	_	_	
22-9	3537-3539	an	_	_	
22-10	3540-3549	important	_	_	
22-11	3550-3567	biopharmaceutical	_	_	
22-12	3568-3574	factor	_	_	
22-13	3575-3578	for	_	_	
22-14	3579-3584	their	_	_	
22-15	3585-3593	cellular	_	_	
22-16	3594-3609	bioavailability	_	_	
22-17	3609-3610	.	_	_	

#Text=However, there are no CPPs available in the art, which are on the one hand side stable enough to carry their cargo to the target before they are metabolically cleaved, and which on the other hand side can be cleared from the tissue before they can accumulate and reach toxic levels.
#Text=[0013] One further approach in the art for delivering cargo molecules into cells, e.g. for gene therapy, comprises peptide ligands (see Martin and Rice (see Martin and Rice, The AAPS Journal 2007; 9 (1) Article 3)).
23-1	3611-3618	However	_	_	
23-2	3618-3619	,	_	_	
23-3	3620-3625	there	_	_	
23-4	3626-3629	are	_	_	
23-5	3630-3632	no	_	_	
23-6	3633-3637	CPPs	_	_	
23-7	3638-3647	available	_	_	
23-8	3648-3650	in	_	_	
23-9	3651-3654	the	_	_	
23-10	3655-3658	art	_	_	
23-11	3658-3659	,	_	_	
23-12	3660-3665	which	_	_	
23-13	3666-3669	are	_	_	
23-14	3670-3672	on	_	_	
23-15	3673-3676	the	_	_	
23-16	3677-3680	one	_	_	
23-17	3681-3685	hand	_	_	
23-18	3686-3690	side	_	_	
23-19	3691-3697	stable	_	_	
23-20	3698-3704	enough	_	_	
23-21	3705-3707	to	_	_	
23-22	3708-3713	carry	_	_	
23-23	3714-3719	their	_	_	
23-24	3720-3725	cargo	_	_	
23-25	3726-3728	to	_	_	
23-26	3729-3732	the	_	_	
23-27	3733-3739	target	_	_	
23-28	3740-3746	before	_	_	
23-29	3747-3751	they	_	_	
23-30	3752-3755	are	_	_	
23-31	3756-3769	metabolically	_	_	
23-32	3770-3777	cleaved	_	_	
23-33	3777-3778	,	_	_	
23-34	3779-3782	and	_	_	
23-35	3783-3788	which	_	_	
23-36	3789-3791	on	_	_	
23-37	3792-3795	the	_	_	
23-38	3796-3801	other	_	_	
23-39	3802-3806	hand	_	_	
23-40	3807-3811	side	_	_	
23-41	3812-3815	can	_	_	
23-42	3816-3818	be	_	_	
23-43	3819-3826	cleared	_	_	
23-44	3827-3831	from	_	_	
23-45	3832-3835	the	_	_	
23-46	3836-3842	tissue	_	_	
23-47	3843-3849	before	_	_	
23-48	3850-3854	they	_	_	
23-49	3855-3858	can	_	_	
23-50	3859-3869	accumulate	_	_	
23-51	3870-3873	and	_	_	
23-52	3874-3879	reach	_	_	
23-53	3880-3885	toxic	_	_	
23-54	3886-3892	levels	_	_	
23-55	3892-3893	.	_	_	
23-56	3894-3895	[	_	_	
23-57	3895-3899	0013	_	_	
23-58	3899-3900	]	_	_	
23-59	3901-3904	One	_	_	
23-60	3905-3912	further	_	_	
23-61	3913-3921	approach	_	_	
23-62	3922-3924	in	_	_	
23-63	3925-3928	the	_	_	
23-64	3929-3932	art	_	_	
23-65	3933-3936	for	_	_	
23-66	3937-3947	delivering	_	_	
23-67	3948-3953	cargo	_	_	
23-68	3954-3963	molecules	_	_	
23-69	3964-3968	into	_	_	
23-70	3969-3974	cells	_	_	
23-71	3974-3975	,	_	_	
23-72	3976-3979	e.g	_	_	
23-73	3979-3980	.	_	_	
23-74	3981-3984	for	_	_	
23-75	3985-3989	gene	_	_	
23-76	3990-3997	therapy	_	_	
23-77	3997-3998	,	_	_	
23-78	3999-4008	comprises	_	_	
23-79	4009-4016	peptide	_	_	
23-80	4017-4024	ligands	_	_	
23-81	4025-4026	(	_	_	
23-82	4026-4029	see	_	_	
23-83	4030-4036	Martin	_	_	
23-84	4037-4040	and	_	_	
23-85	4041-4045	Rice	_	_	
23-86	4046-4047	(	_	_	
23-87	4047-4050	see	_	_	
23-88	4051-4057	Martin	_	_	
23-89	4058-4061	and	_	_	
23-90	4062-4066	Rice	_	_	
23-91	4066-4067	,	_	_	
23-92	4068-4071	The	_	_	
23-93	4072-4076	AAPS	_	_	
23-94	4077-4084	Journal	_	_	
23-95	4085-4089	2007	_	_	
23-96	4089-4090	;	_	_	
23-97	4091-4092	9	_	_	
23-98	4093-4094	(	_	_	
23-99	4094-4095	1	_	_	
23-100	4095-4096	)	_	_	
23-101	4097-4104	Article	_	_	
23-102	4105-4106	3	_	_	
23-103	4106-4107	)	_	_	
23-104	4107-4108	)	_	_	
23-105	4108-4109	.	_	_	

#Text=Peptide ligands can be short sequences taken from larger proteins that represent the essential amino acids needed for receptor recognition, such as EGF peptide used to target cancer cells.
24-1	4110-4117	Peptide	_	_	
24-2	4118-4125	ligands	_	_	
24-3	4126-4129	can	_	_	
24-4	4130-4132	be	_	_	
24-5	4133-4138	short	_	_	
24-6	4139-4148	sequences	_	_	
24-7	4149-4154	taken	_	_	
24-8	4155-4159	from	_	_	
24-9	4160-4166	larger	_	_	
24-10	4167-4175	proteins	_	_	
24-11	4176-4180	that	_	_	
24-12	4181-4190	represent	_	_	
24-13	4191-4194	the	_	_	
24-14	4195-4204	essential	_	_	
24-15	4205-4210	amino	_	_	
24-16	4211-4216	acids	_	_	
24-17	4217-4223	needed	_	_	
24-18	4224-4227	for	_	_	
24-19	4228-4236	receptor	_	_	
24-20	4237-4248	recognition	_	_	
24-21	4248-4249	,	_	_	
24-22	4250-4254	such	_	_	
24-23	4255-4257	as	_	_	
24-24	4258-4261	EGF	_	_	
24-25	4262-4269	peptide	_	_	
24-26	4270-4274	used	_	_	
24-27	4275-4277	to	_	_	
24-28	4278-4284	target	_	_	
24-29	4285-4291	cancer	_	_	
24-30	4292-4297	cells	_	_	
24-31	4297-4298	.	_	_	

#Text=Other peptide ligands have been identified including the ligands used to target the lectin-like oxidized LDL receptor (LOX-1).
25-1	4299-4304	Other	_	_	
25-2	4305-4312	peptide	_	_	
25-3	4313-4320	ligands	_	_	
25-4	4321-4325	have	_	_	
25-5	4326-4330	been	_	_	
25-6	4331-4341	identified	_	_	
25-7	4342-4351	including	_	_	
25-8	4352-4355	the	_	_	
25-9	4356-4363	ligands	_	_	
25-10	4364-4368	used	_	_	
25-11	4369-4371	to	_	_	
25-12	4372-4378	target	_	_	
25-13	4379-4382	the	_	_	
25-14	4383-4394	lectin-like	_	_	
25-15	4395-4403	oxidized	_	_	
25-16	4404-4407	LDL	_	_	
25-17	4408-4416	receptor	_	_	
25-18	4417-4418	(	_	_	
25-19	4418-4421	LOX	_	_	
25-20	4421-4422	-	_	_	
25-21	4422-4423	1	_	_	
25-22	4423-4424	)	_	_	
25-23	4424-4425	.	_	_	

#Text=Up-regulation of LOX-1 in endothelial cells is associated with dysfunctional states such as hypertension and atherosclerosis.
26-1	4426-4439	Up-regulation	_	_	
26-2	4440-4442	of	_	_	
26-3	4443-4446	LOX	_	_	
26-4	4446-4447	-	_	_	
26-5	4447-4448	1	_	_	
26-6	4449-4451	in	_	_	
26-7	4452-4463	endothelial	_	_	
26-8	4464-4469	cells	_	_	
26-9	4470-4472	is	_	_	
26-10	4473-4483	associated	_	_	
26-11	4484-4488	with	_	_	
26-12	4489-4502	dysfunctional	_	_	
26-13	4503-4509	states	_	_	
26-14	4510-4514	such	_	_	
26-15	4515-4517	as	_	_	
26-16	4518-4530	hypertension	_	_	
26-17	4531-4534	and	_	_	
26-18	4535-4550	atherosclerosis	_	_	
26-19	4550-4551	.	_	_	

#Text=Such peptide ligands, however, are not suitable for many gene therapeutic approaches, as they cannot be linked to their cargo molecules by complexation or adhesion but require covalent bonds, e.g. crosslinkers, which typically exhibit cytotoxic effects in the cell.
27-1	4552-4556	Such	_	_	
27-2	4557-4564	peptide	_	_	
27-3	4565-4572	ligands	_	_	
27-4	4572-4573	,	_	_	
27-5	4574-4581	however	_	_	
27-6	4581-4582	,	_	_	
27-7	4583-4586	are	_	_	
27-8	4587-4590	not	_	_	
27-9	4591-4599	suitable	_	_	
27-10	4600-4603	for	_	_	
27-11	4604-4608	many	_	_	
27-12	4609-4613	gene	_	_	
27-13	4614-4625	therapeutic	_	_	
27-14	4626-4636	approaches	_	_	
27-15	4636-4637	,	_	_	
27-16	4638-4640	as	_	_	
27-17	4641-4645	they	_	_	
27-18	4646-4652	cannot	_	_	
27-19	4653-4655	be	_	_	
27-20	4656-4662	linked	_	_	
27-21	4663-4665	to	_	_	
27-22	4666-4671	their	_	_	
27-23	4672-4677	cargo	_	_	
27-24	4678-4687	molecules	_	_	
27-25	4688-4690	by	_	_	
27-26	4691-4703	complexation	_	_	
27-27	4704-4706	or	_	_	
27-28	4707-4715	adhesion	_	_	
27-29	4716-4719	but	_	_	
27-30	4720-4727	require	_	_	
27-31	4728-4736	covalent	_	_	
27-32	4737-4742	bonds	_	_	
27-33	4742-4743	,	_	_	
27-34	4744-4747	e.g	_	_	
27-35	4747-4748	.	_	_	
27-36	4749-4761	crosslinkers	_	_	
27-37	4761-4762	,	_	_	
27-38	4763-4768	which	_	_	
27-39	4769-4778	typically	_	_	
27-40	4779-4786	exhibit	_	_	
27-41	4787-4796	cytotoxic	_	_	
27-42	4797-4804	effects	_	_	
27-43	4805-4807	in	_	_	
27-44	4808-4811	the	_	_	
27-45	4812-4816	cell	_	_	
27-46	4816-4817	.	_	_	
